Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07510386

CGM After Discharge From Hospital

This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Steroid-Induced Diabetes

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult 18 years or older.
  • Inpatient treatment for type 2 or steroid induced diabetes during hospitalization, with plan for insulin use after discharge.

Exclusion criteria

  • Type 1 diabetes
  • Plan for discharge to rehabilitation/skilled nursing/hospice facility
  • Contra-indication to sensor placement
  • Pregnancy

Treatment and study plan

Libre 3 Plus continuous glucose monitoring (CGM) system

Device

Use of unmasked CGM after discharge

Blinded Continuous Glucose Monitoring

Device

Masked CGM

Finger stick

Behavioral

Self-monitoring blood glucose

Primary outcomes

  1. time in range 70-180 mg/dl

    Time frame: Day 20-30

    percent time in range for last 10 days of study

Secondary outcomes

  1. 30 day time in range

    Time frame: Day 30

    Overall 30 day time in range

  2. Percent time >180mg/dL

    Time frame: Day 30

    percent time in range on day 30

  3. Percent time >250mg/dL

    Time frame: Day 30

    percent time in range on day 30

  4. Percent time <70mg/dL

    Time frame: Day 30

    percent time in range on day 30

  5. Percent time <54mg/dL

    Time frame: Day 30

    percent time in range on day 30

Study contacts

Contact information is provided by the study sponsor or research team.

Sophie Baum

CONTACT

[email protected]

212-241-7173

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Registry information

Official study title

Continuous Glucose Monitoring for Post-discharge Diabetes Management

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 3, 2026
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.